



BUY & BILL BASICS:

SIMPLIFYING THE PROCESS OF GETTING PATIENTS ON ZILRETTA

As a provider-administered product, ZILRETTA is covered by most health plans as a medical benefit. However, coverage varies from patient to patient and plan to plan, so there are slightly different requirements and steps along the way.

| | | |
|---|--|---|
| 1 | CONFIRM PATIENT'S COVERAGE | |
| | <p>Medicare Part B Fee-for-Service (FFS) —Most common, Buy & Bill is required</p> <ul style="list-style-type: none">• ZILRETTA has open access• No restrictions at the local level• No prior authorization (PA) required• Patient is eligible for treatment immediately• Code and bill (J3304)  | <p>Commercial and Medicare Part C (Advantage) — Very common, may also offer an option for Specialty Pharmacy</p> <ul style="list-style-type: none">• ZILRETTA access is strong• Specific coverage, authorizations, and fees vary• FlexForward® can offer a range of support and assistance:<ul style="list-style-type: none">- Determine coverage- Verify benefits- Assist with preauthorization where needed  |
| 2 | ORDER ZILRETTA The practice orders the product from suppliers. Scan the QR code on the back or visit ZilrettaPro.com/buyandbill to see the full list of distributors | |
| 3 | SCHEDULE THE TREATMENT Once benefits are confirmed, payer requirements are met, and ZILRETTA has been ordered, schedule an appointment for your patient's treatment | |
| 4 | TREATMENT On the day of the treatment, collect co-pay or co-insurance from the patient. Document the treatment and prepare the documentation to provide to the payer | |
| 5 | SUBMIT THE CLAIM Complete claim forms with appropriate documentation and submit. Keep in mind, clean claims can help streamline processing and payment | |
| 6 | RECONCILE YOUR REIMBURSEMENT Upon receipt of remittance, ensure that it is in line with expectations. If the claim is denied, or paid in part, review the Buy & Bill process and make sure it was submitted properly. If you believe the claim was improperly denied, FlexForward can assist with a review of the documentation | |



PACIRA IS HERE TO HELP YOU AND YOUR PATIENTS

Scan this QR code or visit ZilrettaPro.com/buyandbill for access to a full distributor list and more detailed information on the Buy & Bill process for ZILRETTA



INDICATION AND IMPORTANT SAFETY INFORMATION

Indication

ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.

Limitation of Use: The efficacy and safety of repeat administration of ZILRETTA have not been demonstrated.

Contraindication

ZILRETTA is contraindicated in patients who are hypersensitive to triamcinolone acetonide, corticosteroids, or any components of the product.

Warnings and Precautions

- **Intra-articular Use Only:** ZILRETTA has not been evaluated and should not be administered by epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, or subcutaneous routes. Serious events have been reported with epidural and intrathecal administration of corticosteroids and none are approved for this use. ZILRETTA should not be considered safe for epidural or intrathecal administration.
- **Hypersensitivity Reactions:** Rare instances of anaphylaxis, including serious cases, have occurred in patients with hypersensitivity to corticosteroids.
- **Joint Infection and Damage:** A marked increase in pain accompanied by local swelling, restriction of joint motion, fever, and malaise are suggestive of septic arthritis. Examine joint fluid to exclude a septic process. If diagnosis is confirmed, institute appropriate antimicrobial therapy. Avoid injecting corticosteroids into a previously infected or unstable joint. Intra-articular administration may result in damage to joint tissues.
- **Increased Risk of Infections:** Infection with any pathogen in any location of the body may be associated with corticosteroid use. Corticosteroids may increase the susceptibility to new infection and decrease resistance and the ability to localize infection.
- **Alterations in Endocrine Function:** Corticosteroids can produce reversible hypothalamic-pituitary-adrenal axis suppression, with potential for adrenal insufficiency after withdrawal of treatment, which may persist for months. In situations of stress during that period, institute corticosteroid replacement therapy.
- **Cardiovascular and Renal Effects:** Corticosteroids can cause blood pressure elevation, salt and water retention, and increased potassium excretion. Monitor patients with congestive heart failure, hypertension, and renal insufficiency for edema, weight gain, and electrolyte imbalance. Dietary salt restriction and potassium supplementation may be needed.
- **Increased Intraocular Pressure:** Corticosteroid use may be associated with increased intraocular pressure. Monitor patients with elevated intraocular pressure for potential treatment adjustment.
- **Gastrointestinal Perforation:** Corticosteroid administration may increase risk of gastrointestinal perforation in patients with certain GI disorders and fresh intestinal anastomoses. Avoid corticosteroids in these patients.
- **Alterations in Bone Density:** Corticosteroids decrease bone formation and increase bone resorption. Special consideration should be given to patients with or at increased risk of osteoporosis prior to treatment.
- **Behavior and Mood Disturbances:** Corticosteroids may cause adverse psychiatric reactions. Prior to treatment, special consideration should be given to patients with previous or current emotional instability or psychiatric illness. Advise patients to immediately report any behavior or mood disturbances.

Adverse Reactions

The most commonly reported adverse reactions (incidence $\geq 1\%$) in clinical studies included sinusitis, cough, and contusions.

Please see full Prescribing Information at www.ZILRETTALabel.com/PI.pdf.

For more information, please visit www.ZilrettaPro.com or call 1-855-793-9727.



©2023 Pacira Pharmaceuticals, Inc., a wholly owned subsidiary of Pacira BioSciences, Inc. All rights reserved. ZILRETTA and FLEXFORWARD are registered trademarks of Pacira Therapeutics, Inc., a wholly owned subsidiary of Pacira BioSciences, Inc. January 2024. PP-ZA-US-0709